InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

Bausch + Lomb moved to bolster the eye-care company's pipeline of clinical-stage offerings with the acquisition of Whitecap Biosciences, a firm developing two therapies for potential use in glaucoma ...

Jersey City-based Character Biosciences has announced a collaboration with Bausch + Lomb to develop innovative treatments for ...

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Bausch + Lomb Corporation (NYSE:BLCO) stands against the other best ...

The stock of eyecare company Bausch + Lomb Corp. was up 14%on Monday ... issues given its Restasis has a 45% share of the prescription dry-eye market. “Given these points, a sale to a strategic ...

VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX ... Although there is currently no cure for glaucoma, early intervention – including prescription eye drops – can help slow the disease’s ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national nonprofit ...